Zevtera-Ceftobiprole Medocaril Sodium
Zevtera is an advanced-generation cephalosporin antibiotic for treating Staphylococcus aureus bacteremia, including right-sided endocarditis, skin infections, and pneumonia in both adults and children. It works by blocking bacterial cell wall synthesis and remains active against MRSA and resistant strains.
Lumisight-Pegulicianine
Lumisight is an IV fluorescent imaging agent used during lumpectomy to highlight residual breast cancer tissue inside the surgical cavity. This real-time tool helps surgeons ensure more complete tumor removal and aims to lower the need for additional surgery.
Livdelzi-Seladelpar
Livdelzi is used to treat primary biliary cholangitis (PBC). The purpose of Livdelzi is to efficiently target PPARδ, a peroxisome proliferator-activated receptor delta that inhibits the formation of bile acids.
Lazcluze-Lazertinib
Lazcluze (lazertinib) is an oral targeted therapy used with amivantamab for adults with advanced EGFR-mutated non‑small cell lung cancer. This regimen blocks mutant EGFR to delay disease progression, extending median progression-free survival to about 23.7 months.
Miplyffa-Arimoclomol
Miplyffa is used to treat Niemann-Pick disease type C. The combination of the drug Miplyffa and miglustat is suggested for the treatment of neurological symptoms of Niemann-Pick disease type C in adults as well as children who are at least two years old.
Aqneursa-Levacetylleucine
Aqneursa is an oral granule formulation for patients aged 4 years and older with Niemann‑Pick disease type C. It improves neurological symptoms like coordination and balance by enhancing mitochondrial and lysosomal function and reducing cholesterol buildup in nerve cells.
Cobenfy-Xanomeline And Trospium Chloride
Cobenfy is used to treat schizophrenia. It is the first and only FDA-approved medication for schizophrenia. This drug works by activating muscarinic acetylcholine receptors, which are small proteins in the brain.
Flyrcado-Flurpiridaz F 18
Flyrcado is an IV PET imaging agent for adults with known or suspected coronary artery disease. It highlights blood flow to the heart under rest or stress, helping doctors accurately detect ischemia or areas at risk of infarction.
Itovebi-Inavolisib
Itovebi is an oral targeted therapy, added to palbociclib and fulvestrant, for HR-positive, HER2-negative advanced breast cancer with PIK3CA mutations. It inhibits mutant PI3Kα to slow tumor progression and extend progression-free survival.
Voranigo-Vorasidenib
Voranigo is an oral treatment for adults and teens with Grade 2 astrocytoma or oligodendroglioma that carry an IDH1 or IDH2 mutation, used after surgery. It blocks mutant IDH enzymes to slow tumor progression, significantly extending the time before disease worsens
